Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer
WELCOME to
    GBC e - journal
      Editor-in-Chief, D. Roukos, MD, PhD
WEB
LAST UPDATE: February10, 2020
    GBCNC Web Site       Associate Editor, J Ajani, MD Anderson, Houston, Texas
FOCUS
2010
The GBC e-journal expands scientific topics, beyond Gastric & Breast Cancer to all cancer types, with special interest in Cancer Precision Medicine
GBC
E JOURNAL
SERVICES
ARCHIVE
DOIs
REGISTER
    LOG IN
    NEW USER

SUBSCRIBE

NLM/NIH is a new subscriber to GBC

INDIVIDUALS
INSTITUTIONS/ LIBRARIES
SUBMIT A MANUSCRIPT
Call for papers
Instruction
Copyright
Conflict
REVIEWERS
Contact Us
 
GBC

First Issue 2020

 
 
 
 
 
 
 
 
 
 
 
  SELECTED CITATIONS IN HIGH-IMPACT JOURNALS
  PAPER CITATION Impact Factor
1
Roukos DH, et al. Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol. 2002 Dec;9(10):941-3.
Trusheim MR(1), Berndt ER, Douglas FL. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov. 2007 Apr;6(4):287-93.
57.618
2
Roukos DH, Briasoulis E. Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome. Nat Clin Pract Oncol. 2007 Oct;4(10):578-90. Review.
Zhang L, Jing D, Jiang N, et al. Transformable peptide nanoparticles arrest HER2 signalling and cause cancer cell death in vivo. Nat Nanotechnol. 2020 Jan 27.
33.407
3
Lianos GD, Alexiou GA, et al, Roukos DH. The role of heat shock proteins in cancer. Cancer Lett. 2015 May 1;360(2):114-8.
Nieto MA, Huang RY, et al. EMT: 2016. Cell. 2016 Jun 30;166(1):21-45.
36.216
4
Lianos GD, Alexiou GA, et al, Roukos DH. The role of heat shock proteins in cancer. Cancer Lett. 2015 May 1;360(2):114-8.
Manasanch EE, Orlowski RZ. Proteasome inhibitors in cancer therapy. Nat Rev Clin Oncol. 2017 Jul;14(7):417-433.
34.106
5
Kyrochristos ID, Ziogas DE, Roukos DH. Dynamic genome and transcriptional network-based biomarkers and drugs: precision in breast cancer therapy. Med Res Rev. 2019 May;39(3):1205-1227.
Andrei L(1), Kasas S(2), Ochoa Garrido I(3), et al. Advanced technological tools to study multidrug resistance in cancer. Drug Resist Updat. 2020 Jan;48:100658.
11.708
6
Roukos, D.H., Kappas, A.M. Perspectives in the treatment of gastric cancer. (2005) Nature Clinical Practice Oncology, 2 (2), pp. 98-107.
Lu Y, Lemon W, Liu PY, et al. A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med. 2006 Dec;3(12):e467.
11.048
GBC
TOP 10 Cancer Precision Medicine (CPM) papers in 2019
* The selection was based on:
1. Validity of data
2. Innovation
3. Potential fast translation into the clinic.
 
1. Sabarinathan R, Pich O, Martincorena I, et al. The PCAWG Drivers and Functional Interpretation Group and the ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Network. The whole-genome panorama of cancer drivers.
This pre-print on the PCAWG Consortium will be published in Nature, 2020.
 
2. Wan N, Weinberg D, Liu TY, et al. Machine learning enables detection of early-stage colorectal cancer by whole-genome sequencing of plasma cell-free DNA. BMC Cancer. 2019 Aug 23;19(1):832. doi: 10.1186/s12885-019-6003-8.
This is a pre-print in BioRxiv.
 
3. Wang H, Nakamura M, Abbott TR, et al. CRISPR-mediated live imaging of genome editing and transcription. Science. 2019 Sep 20;365(6459):1301-1305. doi: 10.1126/science.aax7852.
 
4. Demircioglu D, Cukuroglu E, Kindermans MA, et al. Pan-cancer Transcriptome Analysis Reveals Pervasive Regulation through Alternative Promoters. Cell. 2019 Sep 5;178(6):1465-1477.e17. doi: 10.1016/j.cell.2019.08.018.
 
5. PCAWG Transcriptome Core Group; Calabrese C, Davidson NR, Fonseca1 NA, et al. Genomic basis for RNA alterations revealed by whole-genome analyses of 27 cancer types.
This pre-print on the PCAWG Consortium will be published in Nature, 2020.
 
6. Porteus MH. A New Class of Medicines through DNA Editing. N Engl J Med. 2019 Mar 7;380(10):947-959. doi: 10.1056/NEJMra1800729.
 
7. Ligorio M, Sil S, Malagon-Lopez J, Nieman LT, et al. Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer. Cell. 2019 Jun 27;178(1):160-175.e27. doi: 10.1016/j.cell.2019.05.012.
 
8. Kyrochristos ID, Roukos DH. Comprehensive intra-individual genomic and transcriptional heterogeneity: Evidence-based Colorectal Cancer Precision Medicine. Cancer Treat Rev. 2019 Nov;80:101894. doi: 10.1016/j.ctrv.2019.101894.
 
9. Kyrochristos ID, Ziogas DE, Roukos DH. Dynamic genome and transcriptional network?based biomarkers and drugs: precision in breast cancer therapy. Med Res Rev. 2019 May;39(3):1205-1227. doi: 10.1002/med.21549.
 
10. Kyrochristos ID, Ziogas DE, Roukos DH. Drug resistance: origins, evolution and characterization of genomic clones and the tumor ecosystem to optimize precise individualized therapy. Drug Discov Today. 2019 Jun;24(6):1281-1294. doi: 10.1016/j.drudis.2019.04.008.
GBC

Past Issue

 
 
 
 
 
 
 
 
 
 
 
 
 
Ιατρική Ακριβείας του Καρκίνου
These landmark papers have attracted scientific interest to: point
point
1.
2.
3.
4.
5.
6.
7.

Nice, May 30, 31, 3rd International COnference on Women Health and Breast Cancer

8.
9.
10.
point

2018

13.
14.
15. Amsterdam, October 18-19, 14th Global Biomarkers Summit
16.
17.
18.
19.
20. Helsinki, November 26-27, International Conference on Epigenetics and Epitranscriptomics
21. Rome, November 26-28, World Structural and Molecular Biology Conference

Online ISSN : 1109 - 7647
Print ISSN : 1109 - 7655 ..

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.

Search only trustworthy HONcode health websites:

last update: 10 February 2020